JUNE 7, 2017 by Sarah Faulkner
ivWatch said today that it closed a $14.8 million financing round to support the company’s direct go-to-market initiatives and strategic partners activities.
Undisclosed angel investors, family funds and a major hospital system invested in the round, according to the company.
“The support ivWatch has seen from our investors and partners has been incredible. They are committed to seeing our technology, research, science and team make a true impact on the problems related to peripheral IV failure,” president & CEO Gary Warren said in prepared remarks. “The momentum we are finding in the market is exciting, as healthcare providers see the benefits of improved patient safety and reduced risks associated with IV therapy.” Read the full article.
Original post published in Drug Delivery Business News on June 7, 2017.